COP1 Deficiency in BRAF^V600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Aberrant mitogen-activated protein kinase (MAPK) signaling drives cancer, but BRAFV600E inhibitor efficacy is limited by drug resistance.
• Mechanisms of resistance, particularly involving post-translational modifications of transcription factors, require further elucidation.

Purpose of the Study:

• To investigate the role of COP1 and DET1 mutations in acquired resistance to BRAFV600E inhibitors.
• To elucidate the mechanism by which CRL4^COP1/DET1 regulates ETV transcription factors and contributes to therapeutic resistance.

Main Methods:

• Analysis of patient tumors with acquired resistance to vemurafenib.
• Investigating the function of CRL4^COP1/DET1 ligase complex in melanoma cells.
• Assessing the impact of COP1/DET1 mutations on ETV protein stability and gene expression.
• Evaluating the effect of BCL2A1 deletion on drug sensitivity.

Main Results:

• Patient tumors developed COP1 or DET1 mutations conferring resistance to vemurafenib.
• Mutations inactivated CRL4^COP1/DET1, leading to stabilization of ETV1, ETV4, and ETV5.
• ETV5 stabilization promoted cell survival and BCL2A1 expression.
• Deletion of BCL2A1 re-sensitized resistant cells to vemurafenib.

Conclusions:

• Inactivation of CRL4^COP1/DET1 by COP1/DET1 mutations drives therapeutic resistance in BRAFV600E-mutant melanoma.
• Post-translational regulation of ETV5 by CRL4^COP1/DET1 is critical for controlling pro-survival gene expression.
• Targeting ETV5 or downstream effectors like BCL2A1 represents a potential strategy to overcome resistance in MAPK-driven cancers.